Chemomobilization with (R)-ICE (rituximab, ifosfamide, carboplatin, etoposide) compared to G-CSF and plerixafor (G+P) mobilization in lymphoid malignancies.
Lauren Veltri(West Virginia University), Abraham S. Kanate(HonorHealth), Mehdi Hamadani(Medical College of Wisconsin), Parameswaran Hari(Medical College of Wisconsin), Sijin Wen(The University of Texas MD Anderson Cancer Center), Jean Esselman(Medical College of Wisconsin), Binod Dhakal(Medical College of Wisconsin), Arun K. Singavi(Medical College of Wisconsin), Timothy S. Fenske(Medical College of Wisconsin), Michael Craig(Edith Cowan University), Marcelo C. Pasquini(Cleveland Clinic), Aaron Cumpston(West Virginia University Hospitals), Luo Jin(West Virginia University), Alexandra Shillingburg(West Virginia University)
Cited by 0
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718